Table 2.
Course of IBD and incident cancer stratified by IBD activity at cancer diagnosis.
| Variable | Total | IBD inactive at cancer diagnosis (n=400) | IBD active at cancer diagnosis (n=47) |
|---|---|---|---|
| Development of active IBD* if in remission at cancer diagnosis | - | 112 (28%) | - |
| Remission of IBD if active at cancer diagnosis | - | - | 14 (29.8%) |
| IBD Immunosuppression discontinued for cancer | 31/74 (41.9%) | 27/60 (45.0%) | 4/14 (28.6%) |
| IBD treatment during cancer treatment | |||
| 5-ASA | 188 (42.1%) | 157 (39.3%) | 31 (66.0%) |
| Steroids | 40 (8.9%) | 28 (7.0%) | 12 (25.5%) |
| Immunomodulators | 41 (9.2%) | 33 (8.3%) | 8 (17.0%) |
| Biologics | 24 (5.4%) | 15 (3.8%) | 9 (19.1%) |
| Infliximab | 9 (37.5%) | 6 (40%) | 3 (33.3%) |
| Adalimumab | 9 (37.5%) | 6 (40%) | 3 (33.3%) |
| Certolizumab pegol | 0 | 0 | 0 |
| Golimumab | 1 (4.7%) | 1 (6.7%) | 0 |
| Vedolizumab | 5 (20.8%) | 2 (13.3%) | 3 (33.3%) |
| Ustekinumab | 0 | 0 | 0 |
| IBD treatment after cancer treatment | |||
| 5-ASA | 260 (58.2%) | 225 (56.3%) | 35 (74.5%) |
| Steroids | 94 (21.0%) | 76 (19.0%) | 18 (38.3%) |
| Immunomodulators | 66 (14.8%) | 54 (13.5%) | 12 (25.5%) |
| Biologics | 64 (14.3%) | 50 (12.5%) | 14 (29.8%) |
| Infliximab | 26 (37.7%) | 23 (46%) | 3 (15.8%) |
| Adalimumab | 20 (30%) | 14 (28%) | 6 (31.6%) |
| Certolizumab pegol | 1 (1.4%) | 0 | 1 (5.3%) |
| Golimumab | 2 (2.9%) | 1 (2%) | 1 (5.3%) |
| Vedolizumab | 17 (24.6%) | 10 (5%) | 7 (36.8%) |
| Ustekinumab | 3 (4.3%) | 2 (4%) | 1 (5.3%) |
| Complication of IBD after cancer treatment | |||
| IBD-related hospitalization | 46 (10.3%) | 31 (7.8%) | 15 (31.9%) |
| IBD-related surgery | 29 (6.5%) | 21 (5.3%) | 8 (17.0%) |
| Median duration of follow up, months (range) | 95 (2–444) | 99 (2–444) | 54 (1–280) |
*
IBD-related surgery, hospital admission, disease complication, steroid prescription, or endoscopic recurrence requiring a change in IBD management